Company: Fred Hutchinson Cancer Research Center
Job title: Director, Protein Therapeutics
Dr. Mehlin has been employed for over two decades in the development of both small and large molecule therapeutics. He is a named inventor on over eighteen therapeutic antibody patents, including two that have been approved by the FDA (Repatha, Siliq). He has held a variety of positions in biotech, pharma, and academia, and he is currently leading efforts at the Fred Hutchinson Cancer Research Center to develop paired bispecific antibodies for the treatment of cancer.